Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does METOCLOPRAMIDE Cause Dermatitis exfoliative generalised? 7 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Dermatitis exfoliative generalised have been filed in association with METOCLOPRAMIDE (metoclopramide hydrochloride). This represents 0.1% of all adverse event reports for METOCLOPRAMIDE.

7
Reports of Dermatitis exfoliative generalised with METOCLOPRAMIDE
0.1%
of all METOCLOPRAMIDE reports
2
Deaths
7
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From METOCLOPRAMIDE?

Of the 7 reports, 2 (28.6%) resulted in death, 7 (100.0%) required hospitalization.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for METOCLOPRAMIDE. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does METOCLOPRAMIDE Cause?

Nausea (1,080) Drug ineffective (927) Off label use (926) Drug hypersensitivity (751) Vomiting (672) Dyspnoea (525) Headache (499) Diarrhoea (481) Hypersensitivity (473) Tardive dyskinesia (465)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) DUPILUMAB (162) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) SECUKINUMAB (96) VANCOMYCIN (92) AMLODIPINE (91)

Which METOCLOPRAMIDE Alternatives Have Lower Dermatitis exfoliative generalised Risk?

METOCLOPRAMIDE vs METOLAZONE METOCLOPRAMIDE vs METOPIMAZINE METOCLOPRAMIDE vs METOPROLOL METOCLOPRAMIDE vs METRELEPTIN METOCLOPRAMIDE vs METRONIDAZOLE

Related Pages

METOCLOPRAMIDE Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised METOCLOPRAMIDE Demographics